ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

NCT07158918 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: ABL103
DRUG: KEYTRUDA® (pembrolizumab)
DRUG: Taxane

Sponsor

ABL Bio, Inc.

Collaborators

[object Object]